Comments
Glenmark has received tentative nod from the US health regulator for Saxagliptin tablets.
“Glenmark Pharmaceuticals Inc, USA (Glenmark) has been granted tentative approval by the United States Food & Drug Administration for Saxagliptin tablets, 2.5 mg and 5 mg, the generic version of Onglyza tablets, 2.5 mg and 5 mg of AstraZeneca AB,” the company said in a BSE filing today.
According to IMS Health sales data for the 12-month period ended April 2017, the Onglyza tablets, 2.5 mg and 5 mg market achieved annual sales of approximately $518.5 million.
Glenmark’s current portfolio consists of 117 products authorised for distribution in the US marketplace and 68 ANDAs pending approval with the USFDA, it said.
In addition to these internal filings, Glenmark continues to identify and explore external development partnerships to supplement and accelerate the growth of its existing pipeline and portfolio, it added.
Comments
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.